Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Hereditary Cancer in Clinical Practice
Published in: Hereditary Cancer in Clinical Practice 1/2018

Open Access 01-12-2018 | Retraction Note

Retraction Note to: The BRCA2 variant c.68–7 T > A is associated with breast cancer

Authors: Pål Møller, Eivind Hovig

Published in: Hereditary Cancer in Clinical Practice | Issue 1/2018

Login to get access

Excerpt

This article [1] has been retracted at the request of the authors. Upon re-review of the data, the authors identified coding errors in this study. Due to an error in the SQL query, the conclusions drawn in the article are incorrect. A re-examination of the data shows that there is no association between familial breast cancer and the BRCA2 variant c.68–7 T > A. Another recent study suggests that the variant is not pathogenic [2]. All authors agree to this retraction. …
Literature
1.
2.
Colombo M, et al. The BRCA2 c.68-7T > a variant is not pathogenic: a model for clinical calibration of spliceogenicity. Hum Mutat. 2018;39:729–41.CrossRefPubMed
Metadata
Title
Retraction Note to: The BRCA2 variant c.68–7 T > A is associated with breast cancer
Authors
Pål Møller
Eivind Hovig
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Hereditary Cancer in Clinical Practice / Issue 1/2018
Electronic ISSN: 1897-4287
DOI
https://doi.org/10.1186/s13053-018-0093-1

Other articles of this Issue 1/2018

Hereditary Cancer in Clinical Practice 1/2018 Go to the issue

Research

German National Case Collection for familial pancreatic Cancer (FaPaCa) - acceptance and psychological aspects of a pancreatic cancer screening program

Research

Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds

Research

A retrospective study of extracolonic, non-endometrial cancer in Swedish Lynch syndrome families

Research

Patient and provider perspectives on adherence to and care coordination of lynch syndrome surveillance recommendations: findings from qualitative interviews

Research

Central nervous system gadolinium accumulation in patients undergoing periodical contrast MRI screening for hereditary tumor syndromes

Research

Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits